151 related articles for article (PubMed ID: 33010880)
1. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy.
Corsini EM; Foo WC; Mitchell KG; Zhou N; Maru DM; Ajani JA; Hofstetter WL; ; Correa AM; Antonoff MB; Lin SH; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL
J Thorac Cardiovasc Surg; 2021 Nov; 162(5):1404-1412.e2. PubMed ID: 33010880
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma.
van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP
Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657
[TBL] [Abstract][Full Text] [Related]
3. Signet Ring Cell Histology Confers Worse Overall Survival in Treated Esophageal Adenocarcinoma.
Tang A; Rappaport J; Raja S; Bribriesco AC; Sudarshan M; Siddiqui HU; Raymond D; Murthy SC; Ahmad U
Ann Thorac Surg; 2021 Jan; 111(1):214-222. PubMed ID: 32579884
[TBL] [Abstract][Full Text] [Related]
4. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
[TBL] [Abstract][Full Text] [Related]
6. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
7. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation.
Patel VR; Hofstetter WL; Correa AM; Agarwal A; Rashid A; Bhutani MS; Lin SH; Ajani JA; Swisher SG; Maru DM
Ann Thorac Surg; 2014 Sep; 98(3):1064-71. PubMed ID: 25038008
[TBL] [Abstract][Full Text] [Related]
8. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of the esophagus with signet ring cell features portends a poor prognosis.
Enlow JM; Denlinger CE; Stroud MR; Ralston JS; Reed CE
Ann Thorac Surg; 2013 Dec; 96(6):1927-32. PubMed ID: 23987898
[TBL] [Abstract][Full Text] [Related]
11. Surgically Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database.
Sathe TS; Resio BJ; Hoag JR; Monsalve AF; Pathak R; Blasberg JD; Mase V; Dhanasopon A; Boffa DJ
Ann Thorac Surg; 2020 Jun; 109(6):1656-1662. PubMed ID: 32109449
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
[TBL] [Abstract][Full Text] [Related]
13. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.
Levinsky NC; Wima K; Morris MC; Ahmad SA; Shah SA; Starnes SL; Van Haren RM;
J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2555-2566. PubMed ID: 31767364
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
[TBL] [Abstract][Full Text] [Related]
15. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
McKay SC; Louie BE; Molena D; Andrews WG; Boerner T; Hofstetter WL; Yeung J; Darling GE; Sharata A; Peyre CG; Dunn C; Lipham JC; Marginean H; DeMeester SR
J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1943-1950. PubMed ID: 37788788
[TBL] [Abstract][Full Text] [Related]
16. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation.
Charalampakis N; Nogueras González GM; Elimova E; Wadhwa R; Shiozaki H; Shimodaira Y; Blum MA; Rogers JE; Harada K; Matamoros A; Sagebiel T; Das P; Minsky BD; Lee JH; Weston B; Bhutani MS; Estrella JS; Badgwell BD; Ajani JA
Oncology; 2016; 90(5):239-47. PubMed ID: 27046280
[TBL] [Abstract][Full Text] [Related]
17. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
18. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
